Furthermore, p53 status of stromal cells in tumor environment is reported to influence the drug response of tumor cells [80]; thus, it would be interesting to explore if p53 status in BMSCs from MM patients affects the level of protection for MM cells or their response to anti-myeloma drugs. This evidence concerns the gene TP53 and plasma cell myeloma.